bpc-157 capsules uk BPC157 Peptide (CAPSULE) – Thoroughbred Labs Swiss Chems Oral BPC 157

How IGF-1 LR3 Works Reduced IGFBP binding The N-terminal extension and R3 substitution disrupt binding to IGF-binding proteins, keeping LR3 free in plasma rather than sequestered

Products with 1-2% GHK-Cu concentration in stable formulations with appropriate pH and penetration enhancers create stronger improvements more likely persisting after treatment, while lower concentrations (0.1-0.5%) or degraded products may produce subtle temporary effects disappearing quickly upon discontinuation

A physician-directed topical protocol typically follows a progression

Oral administration: 0.5-1 mg daily to compensate for lower bioavailability compared to injection